Research & Projects

ESCMID Panorama

ESCMID Study Group for Viral Hepatitis - ESGVH

News & Activities

27-28 September 2019, Ljubljana, Slovenia

View the Flyer here

For other ESCMID courses & workshops please refer to this page

  • ECCMID 2015 material
  • ESGVH Business Meeting at ECCMID 2015
  • ESGVH activities (courses, projects, publications)
  • ESGVH membership

This survey aims to detect the controversies and gaps in accessing diagnosis, treatment and management of HBV. This short survey will enable us to get snapshots of the situations in the countries and to analyse them and to discuss solutions. The results will be reported here later.

Please download the HBV survey here and send it completed by 23 August 2013 to .

Your contribution is greatly appreciated.

Resat Ozaras

for the ESGVH Executive Committee

The ESCMID programme committee has notified the study groups recently that 2 of our proposals have been granted. They are:

  • 2‐hour Educational Workshop entitled “Viral infections in pregnancy”. The topics to be discussed are 1) Hepatitis B in pregnancy (Resat Ozaras), 2) Hepatitis C in pregnancy (Marie-Louise Newell) 3) Prevention of mother to child transmission of HIV (François Dabis) and Hepatitis E in pregnancy (Udayakumar Navaneethan);
  • Meet‐the‐Expert Session entitled “The management of HIV/HCV infection in the era of direct active drugs”. Speakers will be Dominique Salmon and David Back.

The ECCMID 2014 preliminary programme will soon be published. Check the congress website for latest updates.

After a number of years and because of ESCMID regulations, during this business meeting, a new executive committee was elected. We wish to thank the previous committee consisting of Dominique Salmon (Chair), Andy Hoepelman (Secretary) and Will Irving (Treasurer) for the outstanding work and enthusiasm for the study group.

As new executive committee the following members have been elected:

Joop Arends (Chair)
Dominique Salmon (Secretary)
Badreddine Kilani (Treasurer)
Ongoing Project

Planning to write a guideline on diagnosis and management for acute HCV in conjunction with ESCMID, ISC, the Japanese Society of Chemotherapy, EASL and industrial companies. Research to finance this activity is ongoing.

Potential collaborative studies

Diagnosis of acute HCV infection is difficult. We are keen to generate a panel of serum/plasma samples from patients known to be undergoing acute infection, in order to validate future diagnostic assays e.g. IgG avidity testing. If you see such patients in your clinics, and have access to blood/serum/plasma samples surplus to diagnostic requirements, we would like to try and create a biobank of such material. Please contact any member of the Executive Committee if you are interested in this endeavour.
Identification of a network of virological laboratories willing to share protocols and laboratory procedures aimed at the validation of new techniques for the diagnosis and monitoring of acute and chronic hepatitis B and C infection and treatment will also be developed in the next months.

Corporate ESGVH membership

A number of special interest groups within ESCMID have opened their doors to corporate membership. The ESGVH executive has also decided to do this, as a way of interesting and involving diagnostic and therapeutic companies in our activities. We believe that progress in the diagnosis and management of viral hepatitis requires collaborative effort and input from both physicians and industry. The ESCMID executive recently released updated "ESCMID Operating Procedures for Study Groups" guiding all Study Group activities - including corporate membership - and subsequently, we have invited a number of companies to join ESGVH. We hope that this will encourage them to organize hepatitis-related symposia at ECCMID, thereby increasing the hepatitis content of those annual meetings. If ESGVH members know of companies that would be interested in joining us, please let a member of the Executive Committee know so that we can send out our standard letter of invitation to them. The standard ESGVH fee for corporate membership is 1'000 Euros, so this also represents a way in which ESGVH can accumulate modest financial support to fund and extend our activities.

  • Definition with a network of virological laboratories of a virological test that can differentiate acute from chronic hepatitis C infections (avidity antibody test)
  • Setting up of a cohort of acute hepatitis C patients in Europe

Download the latest Annual Report.